Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

Bank of New York Mellon Corp cut its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 24.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 166,122 shares of the biopharmaceutical company’s stock after selling 52,439 shares during the period. Bank of New York Mellon Corp owned about 0.26% of MacroGenics worth $540,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Barclays PLC grew its holdings in shares of MacroGenics by 97.1% during the third quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 48,639 shares during the last quarter. SG Americas Securities LLC raised its position in shares of MacroGenics by 104.5% during the 4th quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 17,577 shares during the last quarter. Stifel Financial Corp increased its holdings in MacroGenics by 19.7% in the third quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 6,578 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of MacroGenics by 35.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 566,328 shares of the biopharmaceutical company’s stock valued at $1,863,000 after acquiring an additional 147,438 shares during the period. Finally, FMR LLC boosted its position in shares of MacroGenics by 1,230.1% during the third quarter. FMR LLC now owns 137,215 shares of the biopharmaceutical company’s stock worth $451,000 after purchasing an additional 126,899 shares in the last quarter. 96.89% of the stock is owned by institutional investors and hedge funds.

MacroGenics Stock Down 5.1 %

Shares of NASDAQ:MGNX opened at $1.48 on Friday. MacroGenics, Inc. has a 12-month low of $1.46 and a 12-month high of $19.54. The stock has a market cap of $93.37 million, a PE ratio of -0.94 and a beta of 2.12. The business has a 50 day moving average of $2.54 and a 200-day moving average of $3.17.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. The business had revenue of $49.40 million during the quarter, compared to the consensus estimate of $34.17 million. Equities research analysts expect that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Analyst Ratings Changes

MGNX has been the topic of several recent analyst reports. StockNews.com cut MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 21st. HC Wainwright reduced their price objective on shares of MacroGenics from $4.00 to $2.00 and set a “neutral” rating for the company in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.38.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.